



1615/17

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: **STAMM et al.**

Application No.: **09/899,026**

Group Art Unit: **1615**

Filed: **July 6, 2001**

Examiner: **B. Seidleck**

For: **Fenofibrate Pharmaceutical Composition Having High Bioavailability and Method for Preparing It**

Attorney Docket No.: **107664.115 US3**

Assistant Commissioner of Patents  
Washington, DC 20231

**RECEIVED**  
JAN 28 2002  
TECH CENTER 1600/2900


**Transmittal Letter**

Enclosed herewith for appropriate action by the US Patent Office are the following:

1. Petition for Extension of Time under 37 CFR § 1.136.
2. Response and Amendment Under 37 CFR § 1.111
3. Executed Terminal Disclaimer.

The Commissioner is authorized to charge the fee of **\$110** (extension fee) to Deposit Account No. 08-0219. The Commissioner is authorized to charge any other necessary fees or credit any overpayments to Deposit Account No. 08-0219 to maintain the pendency of the application.

Respectfully submitted,



Edward D. Grieff  
Registration No. 38,898

Date: January 23, 2002  
HALE and DORR LLP  
1455 Pennsylvania Avenue, NW  
Washington, DC 20004  
Phone: (202) 942-8400